Business Context and Reporting Period
This Form 8-K is a current report filed by Myriad Genetics, Inc. on June 17, 2026. The filing addresses a corporate governance event involving the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
Departure of Director: On June 17, 2026, Daniel M. Skovronsky, M.D., Ph.D., resigned from the Board of Directors, effective immediately. The Company stated that the resignation was not the result of any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the standard disclosure regarding the director's departure.
Key Facts for Investor Verification
- Dr. Daniel M. Skovronsky resigned as a director effective June 17, 2026.
- The resignation was not due to any disagreement with the Company.
- The report was signed by Benjamin R. Wheeler, Chief Financial Officer, on June 23, 2026.
- No financial results or operational metrics are included in this specific filing.